Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Proacta obtains FDA clearance for clinical PR-610 study

Aug. 30, 2012

Zytiga sNDA receives priority review status

Aug. 30, 2012

Promising phase IIa data reported on Archexin

Aug. 29, 2012

First patient enrolled in phase IIa AEZS-130 study

Aug. 29, 2012

Novelos Therapeutics developing optical imaging agent for use in cancer

Aug. 29, 2012

Health Canada approves Treanda

Aug. 29, 2012

Esperance advances phase II trial in ovarian cancer

Aug. 29, 2012

Boehringer Ingelheim Pharma patents new PI3K-alpha inhibitors

Aug. 29, 2012

Scientists in U.S. disclose novel HDAC inhibitors

Aug. 29, 2012

New potential cancer therapies developed at U.S. university

Aug. 29, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
Saniona reports preclinical data for SAN-2668
BioWorld Science
Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...